Who Owns Piramal Pharma Solutions?

Piramal Pharma Solutions operates under Piramal Pharma Limited's sustainability framework, built on four pillars: Business Resilience, Quality and Excellence, Responsible Operations, and Stakeholder Centricity. The company has established over 50 time-bound sustainability targets.

The division maintains manufacturing facilities across India, the United States, the United Kingdom, and Europe that comply with environmental regulations and sustainability standards. The company focuses on responsible manufacturing practices, waste reduction, energy efficiency, and sustainable resource management across its production sites.

Piramal Pharma Solutions' manufacturing facilities have been inspected by regulatory authorities including the U.S. FDA, UK MHRA, and other global regulators. The division's commitment to quality is embedded in its operations, with quality treated as a collective responsibility across the organization.

The division collaborates with the Piramal Foundation on CSR programs focused on healthcare access, education, and community development. The Piramal Foundation operates initiatives in rural healthcare, education, and women's empowerment across India.

In 2025, the division's NPS of 55, validated by DNV, reflected its commitment to stakeholder centricity and customer satisfaction. This score demonstrates the division's ability to build trust-based relationships with pharmaceutical industry clients.

The division's expansion strategy includes facility upgrades and new construction projects, such as the ADC manufacturing facility in Grangemouth, Scotland. These investments are made with attention to environmental standards and sustainable business practices.

Piramal Pharma Solutions has received multiple industry awards for its CDMO services and customer satisfaction.

In 2025, the division achieved a Net Promoter Score of 55, validated by third-party provider DNV. This score surpassed industry averages and demonstrated the division's commitment to customer satisfaction and stakeholder centricity.

In 2024, Piramal Pharma Solutions was recognized as a winner in four categories at the CDMO Leadership Awards, spanning overall, small pharma, and big pharma segments. This multi-category recognition demonstrated the division's ability to serve diverse pharmaceutical company needs.

In 2022, the division won in six categories at the CMO Leadership Awards in the small pharma segment. This consistent recognition across multiple years highlights the division's sustained position in the contract manufacturing industry.

The division was named "Top Indian Bioservices Company of the Year" for two consecutive years (2020-21 and 2021-22) at the BioSpectrum Excellence Awards, demonstrating its position in the Indian bioservices sector.

In 2021, the division received the Frost and Sullivan Global CDMO Customer Value Leadership Award, recognizing its ability to deliver value to customers through innovative solutions and operational excellence.

In 2018, the division was awarded "Industry Partner of the Year" at the Global Generics and Biosimilars Awards during the CPhI Conference, highlighting its reputation as a trusted partner in the pharmaceutical industry.

In 2016, the division received the "Best Customer Experience Award of the Year - Pharmaceutical" at Customer Fest, demonstrating an early commitment to customer-centric service delivery.

Piramal Pharma Solutions has not experienced any major product recalls or significant controversies as of August 2026. The division has maintained a strong operational record throughout its history as a CDMO provider.

Quality and Compliance Track Record: The division's manufacturing facilities in India, the United States, the United Kingdom, and Europe have successfully cleared inspections by multiple regulatory authorities, including the U.S. FDA, UK MHRA, and other global regulators. This compliance record reflects the company's investment in quality systems and regulatory expertise.

No Major Product Recalls: As a contract development and manufacturing organization serving pharmaceutical companies, Piramal Pharma Solutions has not experienced any major product recalls. The division's focus on quality as a collective responsibility has contributed to its ability to maintain high standards across all manufacturing processes and client projects.

Limited Public Controversies: Piramal Pharma Solutions has maintained a low public profile with minimal controversies. The company's business-to-business focus on serving pharmaceutical companies rather than direct consumer markets has helped it avoid the types of public scrutiny that affect consumer-facing pharmaceutical companies.

Customer Relationship Strength: The division's NPS of 55 in 2025, validated by DNV, demonstrates the strength of its customer relationships and the absence of significant client disputes. This high customer satisfaction score reflects the division's ability to maintain trust-based relationships with pharmaceutical industry clients.

Parent Company Regulatory Issues: While Piramal Pharma Solutions itself has not been the subject of major regulatory actions, its parent company Piramal Pharma Limited received FDA Form 483 observations at other facilities in 2024 (Michigan) and 2025 (Maharashtra). These actions primarily targeted API manufacturing operations, not the CDMO division's client services. However, the regulatory scrutiny affects the entire company's reputation.